Supplementary Table 5.
Humoral and T-cell immune response after second SARS-CoV-2 vaccination with mRNA/mRNA vs. AZD1222/mRNA
| mRNA/mRNA, median (IQR) |
AZD1222/mRNA, median (IQR) | P | |
|---|---|---|---|
| LC (n = 44 vs 3) | |||
| Anti-S trimer titer, BAU/mL | 1840 (1044–2295) | 6180 (2080–x) | .043 |
| Anti-S RBD titer, U/mL | 3798 (1295–6456) | 22422 (5595–x) | .043 |
| IFN-γ release titer, mIU/mL | N/A | N/A | N/A |
| LT (n = 121 vs 11) | |||
| Anti-S trimer titer, BAU/mL | 163 (11–895) | 1530 (411–4590) | .006 |
| Only responders (≥33.8 BAU/mL) | 641 (186–1535) | 2200 (1081–5310) | .004 |
| Anti-S RBD titer, U/mL | 128 (1–1411) | 4892 (323–15,503) | .004 |
| Only responders (≥0.8 U/mL) | 474 (43–2179) | 5448 (482–17,072) | .007 |
| IFN-γ release titer, mIU/mL | 44 (10–223) | 926 (288–1738) | .004 |
| Only responders (≥100 mIU/mL) | 328 (214–778) | 1151 (602–1919) | .043 |
| Controls (n = 39 vs 11) | |||
| Anti-S trimer titer, BAU/mL | 1610 (1230–2520) | 3260 (1900–5240) | .004 |
| Anti-S RBD titer, U/mL | 2079 (888–5503) | 12194 (8840–14,245) | < .001 |
| IFN-γ release titer, mIU/mL | N/A | N/A | |
Note: Boldface P values indicate statistical significance.
Anti-S RBD, anti-SARS-CoV-2 antibodies in Roche Elecsys immunoassay; anti-S trimer, anti-SARS-CoV-2 antibodies in DiaSorin LIAISON immunoassay; BAU, binding antibody units; IFN-γ, interferon gamma; LT, liver transplant; N/A, not available; RBD, receptor binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2.